AAV-mediated gene transfer to the liver

Area of Science:

• Hepatology
• Gene Therapy
• Molecular Biology

Background:

• The liver's central role in metabolic and synthetic pathways makes it a key target for gene transfer.
• Adeno-associated virus (AAV) is an effective vector for achieving prolonged gene expression in the liver.
• Persistent hepatic gene expression is crucial for treating genetic diseases requiring lifelong enzyme replacement.

Purpose of the Study:

• To evaluate the efficacy of adeno-associated virus (AAV) for in vivo gene transfer to the liver.
• To highlight the potential of AAV-mediated gene therapy for genetic metabolic disorders.
• To discuss the application of AAV for sustained therapeutic gene expression in hepatic tissues.

Main Methods:

• Intravenous (IV) injection of recombinant adeno-associated virus (AAV) into murine models.
• Comparison of peripheral vein versus portal vein injection for liver transduction.
• Assessment of hepatic gene expression levels and duration following AAV administration.

Main Results:

• High-level, persistent hepatic gene expression achieved after a single AAV treatment in animal models.
• Demonstrated therapeutic benefits of AAV vectors in animal models of amino acid disorders, lysosomal storage diseases, and coagulopathies.
• Intravenous AAV injection primarily transduces the liver, with reduced extra-hepatic transduction via portal-vein injection.

Conclusions:

• Adeno-associated virus (AAV) is a powerful tool for achieving sustained gene transfer to the liver.
• AAV-mediated gene therapy holds significant promise for treating inherited metabolic diseases.
• Ongoing research and clinical trials, including for hemophilia B, underscore the therapeutic potential of hepatic AAV gene therapy.